Zydus Lifesciences acquires UK-based LiqMeds Group for Rs 690 crore

Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026 depending on achievement of certain agreed milestones towards acquisition of the LiqMeds Group of companies. The transaction will be EPS accretive for Zydus from the first year of acquisition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IVW5JqE
via IFTTT